Zobrazeno 1 - 10
of 64
pro vyhledávání: '"GOJKOVIĆ, ZDENKA"'
Autor:
Đokanović Dejan, Lazić Bojana, Gojković Zdenka, Cvijetić Željka, Sokolović Emir, Cerić Timur, Jungić Saša
Publikováno v:
Srpski Arhiv za Celokupno Lekarstvo, Vol 151, Iss 3-4, Pp 209-215 (2023)
Introduction/Objective. The purpose of this study was to assess the effectiveness of different approaches in the treatment of metastatic melanoma in daily clinical practice in a situation with limited and late availability of new drugs in a resource-
Externí odkaz:
https://doaj.org/article/991c1c77db1c4c7a9aed6063cf81b701
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Guzijan Aleksandar, Gajanin Radoslav, Ćulum Jovan, Gojković Zdenka, Preradović Ljubiša, Roganović Dragana
Publikováno v:
Scripta Medica, Vol 53, Iss 3, Pp 235-239 (2022)
Background/Aim: Breast-conserving surgery is a type of surgery used as a treatment option for breast cancer. It was introduced at the end of the 20th century following and in accordance with relevant clinical studies. With heightened public awareness
Externí odkaz:
https://doaj.org/article/33bb7ae7fddf4207afe10c1ad73ba839
Autor:
Berendika Jelena, Jungić Saša, Tubić Biljana, Rakita Ivanka, Vještica Milka, Đokanović Dejan, Gojković Zdenka, Mirčeta Nikolina, Petković Sanja, Marković-Peković Vanda
Publikováno v:
Scripta Medica, Vol 53, Iss 1, Pp 29-35 (2022)
Background / Aim: Up until ten years ago stage four melanoma was considered a disease with extremely poor prognosis. Standard therapy during this period of time was dacarbazine chemotherapy. Patients with better performance status were treated with i
Externí odkaz:
https://doaj.org/article/a4296cf8ebac43a1a89356583425e8f0
Autor:
Jungić Saša, Tubić Biljana, Berendika Jelena, Gojković Zdenka, Rakita Ivanka, Vještica Milka, Đokanović Dejan, Gajanin Radoslav
Publikováno v:
Vojnosanitetski Pregled, Vol 79, Iss 8, Pp 796-804 (2022)
Background/Aim. Standard treatment options for the first-line treatment of metastatic colorectal carcinoma (mCRC) are 5-fluorouracil, folinic acid, oxaliplatin (FOL-FOX4)/capecitabine (CapOx), plus bevacizumab (bev) and 5-fluorouracil, folinic acid a
Externí odkaz:
https://doaj.org/article/0644a1e73d9e404cbd2df6715154bbe7
Autor:
Đokanović, Dejan, Gajanin, Radoslav, Gojković, Zdenka, Klokić, Semir, Sladojević, Igor, Gajanin, Vesna, Reljić, Dragana, Jović-Đokanović, Olja, Amidžić, Ljiljana, Marošević, Goran
Publikováno v:
Medicine; 8/16/2024, Vol. 103 Issue 33, p1-13, 13p
Autor:
Dukić Nikolina, Gojković Zdenka, Vladičić-Mašić Jelena, Mašić Srđan, Lalović Nenad, Popović Slađana
Publikováno v:
Archive of Oncology, Vol 26, Iss 1, Pp 10-15 (2020)
Background: Of all breast cancers 20-25% are HER2 positive. Overexpression of HER2 protein on the surface of the malignant cell leads to excessive cell proliferation through different signaling pathways. Trastuzumab is a human monoclonal antibody tha
Externí odkaz:
https://doaj.org/article/adc38fc108bd411f824a917082f8389f
Autor:
CVIJETIĆ, ŽELJKA1 zeljkacvijetic@yahoo.com, GOJKOVIĆ, ZDENKA2, JOVIČIĆ, ŽELJKO1, KOSTUR, SANJA1, BAROŠ, ILIJA1, ŠILJAK, SLAĐANA1
Publikováno v:
Quality of Life: A Multi-Disciplinary Journal of Food Science, Environmental Science & Public Health. 2023, Vol. 14 Issue 1/2, p38-46. 9p.
Autor:
Gojković Zdenka, Đokanović Dejan, Jakovljević Branislava, Maksimović Siniša, Jungić Saša, Rakita Ivanka, Vještica Milka, Rašeta Radmila, Vranješ Živko, Štrbac Marina
Publikováno v:
Scripta Medica, Vol 49, Iss 2, Pp 126-131 (2018)
Introduction: The introduction of BRAF inhibitor vemurafenib significantly improved overall survival (OS) in metastatic melanoma patients. Aim of the Study: The purpose of this study was to determine OS and progression free survival (PFS) in patients
Externí odkaz:
https://doaj.org/article/8d42f34e04634eb0a6eeebcb595a9c55
Publikováno v:
Vojnosanitetski Pregled, Vol 74, Iss 3, Pp 249-255 (2017)
Background/Aim. The efficacy and safety of bevacizumab (BEV) in combination with capecitabin and irinotecan in first-line therapy for patients with metastatic colorectal cancer (mCRC) were studied. In order to improve safety and efficacy of chemother
Externí odkaz:
https://doaj.org/article/4c9e548539c84ce48875dd2e659045d5